论文部分内容阅读
目的探讨胰激肽原肠溶片治疗早期糖尿病肾病(DN)的临床疗效。方法将168例早期2型DN患者,随机分为治疗组和对照组各84例,对照组给以常规的治疗,治疗组在常规治疗的基础上加用胰激肽原肠溶片,两组均治疗3个月,比较2组治疗前后的尿微量白蛋白(mALB)、α1-微球蛋白(α1-MG)、免疫球蛋白G(lgG)、NAG等检测指标。结果与治疗前比较,治疗组治疗后尿mALB、α1-MG、IgG、NAG明显下降,有显著性差异(P<0.05),而对照组指标下降不明显(P>0.05);治疗后两组比较,各项指标均有显著差异(P<0.05)。结论胰激肽原肠溶片治疗早期DN的疗效明显优于单纯常规治疗。
Objective To investigate the clinical efficacy of kallikrein in the treatment of early diabetic nephropathy (DN). Methods A total of 168 patients with early type 2 DN were randomly divided into treatment group (n = 84) and control group (n = 84). The control group was given routine treatment. The treatment group was treated with kallikrein, All the patients were treated for 3 months. The levels of urine microalbumin, α1-microglobulin (α1-MG), immunoglobulin G (IgG) and NAG before and after treatment were compared between the two groups. Results Compared with those before treatment, the levels of urinary mALB, α1-MG, IgG and NAG in the treatment group were significantly decreased (P <0.05), while those in the control group did not decrease significantly (P> 0.05) Compared with each other, there are significant differences (P <0.05). Conclusion The efficacy of pancreatic kallikrein in the treatment of early DN is obviously better than that of conventional treatment.